Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection.

Lampen MH, Uchtenhagen H, Blom K, Varnaitė R, Pakalniene J, Dailidyte L, Wälchli S, Lindquist L, Mickiene A, Michaëlsson J, Schumacher TN, Ljunggren HG, Sandberg JK, Achour A, Gredmark-Russ S.

Immunohorizons. 2018 Jul 2;2(6):172-184. doi: 10.4049/immunohorizons.1800029.

PMID:
31022685
2.

Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy.

Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K.

NPJ Breast Cancer. 2019 Apr 10;5:13. doi: 10.1038/s41523-019-0108-8. eCollection 2019.

3.

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S.

Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678.

4.

Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S.

Oncoimmunology. 2019 Jan 11;8(3):1558663. doi: 10.1080/2162402X.2018.1558663. eCollection 2019.

5.

NK cells specifically TCR-dressed to kill cancer cells.

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S.

EBioMedicine. 2019 Feb;40:106-117. doi: 10.1016/j.ebiom.2019.01.031. Epub 2019 Jan 18.

6.

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.

PMID:
30659053
7.

A Spheroid Killing Assay by CAR T Cells.

Dillard P, Köksal H, Inderberg EM, Wälchli S.

J Vis Exp. 2018 Dec 12;(142). doi: 10.3791/58785.

PMID:
30596389
8.

Treating osteosarcoma with CAR T cells.

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S.

Scand J Immunol. 2019 Mar;89(3):e12741. doi: 10.1111/sji.12741. Epub 2019 Jan 15. Review.

PMID:
30549299
9.

Artesunate shows potent anti-tumor activity in B-cell lymphoma.

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP.

J Hematol Oncol. 2018 Feb 20;11(1):23. doi: 10.1186/s13045-018-0561-0.

10.

Human c-SRC kinase (CSK) overexpression makes T cells dummy.

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S.

Cancer Immunol Immunother. 2018 Apr;67(4):525-536. doi: 10.1007/s00262-017-2105-9. Epub 2017 Dec 16.

PMID:
29248956
11.

A TCR-based Chimeric Antigen Receptor.

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S.

Sci Rep. 2017 Sep 6;7(1):10713. doi: 10.1038/s41598-017-11126-y.

12.

T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth.

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G.

Oncoimmunology. 2017 Mar 17;6(4):e1302631. doi: 10.1080/2162402X.2017.1302631. eCollection 2017.

13.

BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5.

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH.

PLoS One. 2017 May 10;12(5):e0177188. doi: 10.1371/journal.pone.0177188. eCollection 2017.

14.

T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M.

Oncoimmunology. 2016 Oct 24;5(12):e1249090. doi: 10.1080/2162402X.2016.1249090. eCollection 2016.

15.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

16.

Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J.

Oncoimmunology. 2016 Feb 18;5(5):e1138199. doi: 10.1080/2162402X.2016.1138199. eCollection 2016 May.

17.

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.

Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M.

Mol Ther. 2016 Sep;24(9):1675-85. doi: 10.1038/mt.2016.134. Epub 2016 Jul 5.

18.

Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity.

Theodossiou TA, Wälchli S, Olsen CE, Skarpen E, Berg K.

ACS Chem Biol. 2016 Jan 15;11(1):251-62. doi: 10.1021/acschembio.5b00734. Epub 2015 Nov 30.

PMID:
26569462
19.

Unpredicted phenotypes of two mutants of the TcR DMF5.

Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S.

J Immunol Methods. 2015 Oct;425:37-44. doi: 10.1016/j.jim.2015.06.006. Epub 2015 Jun 14.

PMID:
26079729
20.

Soluble T-cell receptors produced in human cells for targeted delivery.

Walseng E, Wälchli S, Fallang LE, Yang W, Vefferstad A, Areffard A, Olweus J.

PLoS One. 2015 Apr 13;10(4):e0119559. doi: 10.1371/journal.pone.0119559. eCollection 2015.

21.

Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.

Kumari S, Wälchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):403-8. doi: 10.1073/pnas.1306549111. Epub 2013 Dec 16.

22.

Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.

Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF.

Eur J Immunol. 2014 Mar;44(3):774-84. doi: 10.1002/eji.201343671. Epub 2013 Dec 27.

23.

BiP negatively affects ricin transport.

Gregers TF, Skånland SS, Wälchli S, Bakke O, Sandvig K.

Toxins (Basel). 2013 May 10;5(5):969-82. doi: 10.3390/toxins5050969.

24.

Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma.

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH.

PLoS One. 2012;7(10):e46117. doi: 10.1371/journal.pone.0046117. Epub 2012 Oct 1.

25.

Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1.

Zhen Y, Sørensen V, Skjerpen CS, Haugsten EM, Jin Y, Wälchli S, Olsnes S, Wiedlocha A.

Traffic. 2012 May;13(5):650-64. doi: 10.1111/j.1600-0854.2012.01341.x. Epub 2012 Mar 4.

26.

A practical approach to T-cell receptor cloning and expression.

Wälchli S, Løset GÅ, Kumari S, Johansen JN, Yang W, Sandlie I, Olweus J.

PLoS One. 2011;6(11):e27930. doi: 10.1371/journal.pone.0027930. Epub 2011 Nov 21.

27.

T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells.

Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Wälchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J.

Int J Cancer. 2012 Apr 15;130(8):1821-32. doi: 10.1002/ijc.26209. Epub 2011 Aug 12.

28.

A single point mutation in ricin A-chain increases toxin degradation and inhibits EDEM1-dependent ER retrotranslocation.

Sokołowska I, Wälchli S, Węgrzyn G, Sandvig K, Słomińska-Wojewódzka M.

Biochem J. 2011 Jun 1;436(2):371-85. doi: 10.1042/BJ20101493.

PMID:
21388347
29.

Transiently redirected T cells for adoptive transfer.

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM.

Cytotherapy. 2011 May;13(5):629-40. doi: 10.3109/14653249.2010.542461. Epub 2010 Dec 21.

PMID:
21174490
30.

Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif.

Abrahamsen IW, Stronen E, Wälchli S, Johansen JN, Kjellevoll S, Kumari S, Komada M, Gaudernack G, Tjonnfjord G, Toebes M, Schumacher TN, Lund-Johansen F, Olweus J.

Leukemia. 2010 Nov;24(11):1901-9. doi: 10.1038/leu.2010.186. Epub 2010 Sep 16.

PMID:
20844564
31.

Splice variants of enigma homolog, differentially expressed during heart development, promote or prevent hypertrophy.

Yamazaki T, Wälchli S, Fujita T, Ryser S, Hoshijima M, Schlegel W, Kuroda S, Maturana AD.

Cardiovasc Res. 2010 Jun 1;86(3):374-82. doi: 10.1093/cvr/cvq023. Epub 2010 Jan 22.

32.

SNX4 in complex with clathrin and dynein: implications for endosome movement.

Skånland SS, Wälchli S, Brech A, Sandvig K.

PLoS One. 2009 Jun 16;4(6):e5935. doi: 10.1371/journal.pone.0005935.

33.

Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin.

Raa H, Grimmer S, Schwudke D, Bergan J, Wälchli S, Skotland T, Shevchenko A, Sandvig K.

Traffic. 2009 Jul;10(7):868-82. doi: 10.1111/j.1600-0854.2009.00919.x. Epub 2009 May 6.

34.

Characterization of clathrin and Syk interaction upon Shiga toxin binding.

Wälchli S, Aasheim HC, Skånland SS, Spilsberg B, Torgersen ML, Rosendal KR, Sandvig K.

Cell Signal. 2009 Jul;21(7):1161-8. doi: 10.1016/j.cellsig.2009.03.005. Epub 2009 Mar 13.

PMID:
19289168
35.

Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.

Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J.

Scand J Immunol. 2009 Apr;69(4):319-28. doi: 10.1111/j.1365-3083.2008.02223.x.

36.

β-arrestins attenuate p38-mediated endosome to Golgi transport.

Skånland SS, Wälchli S, Sandvig K.

Cell Microbiol. 2009 May;11(5):796-807. doi: 10.1111/j.1462-5822.2009.01292.x. Epub 2009 Jan 21.

PMID:
19159388
37.

beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.

Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E.

Exp Hematol. 2009 Feb;37(2):225-33. doi: 10.1016/j.exphem.2008.10.007. Epub 2008 Dec 20. Erratum in: Exp Hematol. 2009 Mar;37(3):421.

PMID:
19101069
38.

Vector-based delivery of siRNAs: in vitro and in vivo challenges.

Walchli S, Sioud M.

Front Biosci. 2008 May 1;13:3488-93.

PMID:
18508450
39.

Phosphorylation of fibroblast growth factor (FGF) receptor 1 at Ser777 by p38 mitogen-activated protein kinase regulates translocation of exogenous FGF1 to the cytosol and nucleus.

Sørensen V, Zhen Y, Zakrzewska M, Haugsten EM, Wälchli S, Nilsen T, Olsnes S, Wiedlocha A.

Mol Cell Biol. 2008 Jun;28(12):4129-41. doi: 10.1128/MCB.02117-07. Epub 2008 Apr 14.

40.

Enigma homolog 1 scaffolds protein kinase D1 to regulate the activity of the cardiac L-type voltage-gated calcium channel.

Maturana AD, Wälchli S, Iwata M, Ryser S, Van Lint J, Hoshijima M, Schlegel W, Ikeda Y, Tanizawa K, Kuroda S.

Cardiovasc Res. 2008 Jun 1;78(3):458-65. doi: 10.1093/cvr/cvn052. Epub 2008 Feb 23.

41.

The Mitogen-activated protein kinase p38 links Shiga Toxin-dependent signaling and trafficking.

Wälchli S, Skånland SS, Gregers TF, Lauvrak SU, Torgersen ML, Ying M, Kuroda S, Maturana A, Sandvig K.

Mol Biol Cell. 2008 Jan;19(1):95-104. Epub 2007 Oct 24.

42.

Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells.

Fujita T, Maturana AD, Ikuta J, Hamada J, Walchli S, Suzuki T, Sawa H, Wooten MW, Okajima T, Tatematsu K, Tanizawa K, Kuroda S.

Biochem Biophys Res Commun. 2007 Sep 28;361(3):605-10. Epub 2007 Jul 23.

PMID:
17669366
43.

Protein kinase Cdelta is activated by Shiga toxin and regulates its transport.

Torgersen ML, Wälchli S, Grimmer S, Skånland SS, Sandvig K.

J Biol Chem. 2007 Jun 1;282(22):16317-28. Epub 2007 Apr 2.

44.

Phosphoinositide-regulated retrograde transport of ricin: crosstalk between hVps34 and sorting nexins.

Skånland SS, Wälchli S, Utskarpen A, Wandinger-Ness A, Sandvig K.

Traffic. 2007 Mar;8(3):297-309.

45.

Transcriptional targeting of small interfering RNAs into cancer cells.

Huynh T, Wälchli S, Sioud M.

Biochem Biophys Res Commun. 2006 Dec 1;350(4):854-9. Epub 2006 Oct 2.

PMID:
17034763
46.

Transport of ricin from endosomes to the Golgi apparatus is regulated by Rab6A and Rab6A'.

Utskarpen A, Slagsvold HH, Iversen TG, Wälchli S, Sandvig K.

Traffic. 2006 Jun;7(6):663-72.

47.

The ESCRT-III subunit hVps24 is required for degradation but not silencing of the epidermal growth factor receptor.

Bache KG, Stuffers S, Malerød L, Slagsvold T, Raiborg C, Lechardeur D, Wälchli S, Lukacs GL, Brech A, Stenmark H.

Mol Biol Cell. 2006 Jun;17(6):2513-23. Epub 2006 Mar 22.

48.

EDEM is involved in retrotranslocation of ricin from the endoplasmic reticulum to the cytosol.

Slominska-Wojewodzka M, Gregers TF, Wälchli S, Sandvig K.

Mol Biol Cell. 2006 Apr;17(4):1664-75. Epub 2006 Feb 1.

49.

Shiga toxin regulates its entry in a Syk-dependent manner.

Lauvrak SU, Wälchli S, Iversen TG, Slagsvold HH, Torgersen ML, Spilsberg B, Sandvig K.

Mol Biol Cell. 2006 Mar;17(3):1096-109. Epub 2005 Dec 21.

50.

Supplemental Content

Loading ...
Support Center